Table 2.
Clinical characteristics of study participants during MDR-TB treatment at St.Peter’s Specialized Hospital and ALERT center, Addis Ababa, Ethiopia
| Clinical characteristics | N(%) | |
|---|---|---|
| Case registration | New case | 77 (8.3) |
| Relapse | 124 (13.3) | |
| After failure of first treatment | 213 (22.9) | |
| After failure of re-treatment | 442 (47.5) | |
| Treatment after being lost to follow- up | 4 (0.4) | |
| Transfer -in | 2 (0.2) | |
| Other | 11 (1.2) | |
| TB treatment in the past | Yes | 788 (84.6) |
| No | 63 (6.8) | |
| Unknown | 27 (2.9) | |
| Treatment taken for past TB | First-line drugs | 792 (85.1) |
| Second- line drugs | 25 (2.7) | |
| Both first and second line drugs | 4 (0.4) | |
| Second- line past injectable treatment | Kanamycin | 1 (0.1) |
| Amikacin | 6 (0.6) | |
| Capreomycin | 17 (1.8) | |
| Streptomycin | 33 (3.5) | |
| Anatomical site TB | Pulmonary | 817 (87.8) |
| Extrapulmonary | 59 (6.3) | |
| MTB detection | Bacteriologically confirmed MDR-TB | 850 (91.3) |
| Clinically diagnosed MDR-TB | 27 (2.9) | |
| NA | 2 (0.2) | |
| MTB confirmation | GeneXpert MTB/RIF positive | 347 (37.5) |
| Culture | 234 (25.1) | |
| Line probe assay | 214 (23.0) | |
| Sputum smear positive | 29 (3.1) | |
| Resistance /Sensitivity testing | GeneXpert MTB/RIF | 356 (38.2) |
| Line probe assay | 232 (24.9) | |
| Phenotypic drug susceptibility testing | 242 (26.0) | |
| NA + other | 42 (4.7) | |
| HIV status | HIV positive MDR-TB patients | 171 (18.4) |
| HIV negative MDR-TB patients | 685 (73.6) | |
| HIV status unknown MDR-TB patients | 23 (2.4) | |
| Pattern of resistance | Isoniazid and rifampicin resistance | 341 (40.1) |
| GeneXpertMTB/RIF rifampicin only resistance | 260 (30.6) | |
| Rifampicin resistance with isoniazid susceptibility | 38 (4.5) | |
| Isoniazid, rifampicin, ethambutol, streptomycin, resistance | 132 (15.5) | |
| Isoniazid, rifampicin and streptomycin resistance | 1 (0.1) | |
| Others | 94 (10.1) | |